Gilead to Acquire PepStar Inflammation Drug Program for $1.28 Billion
Gilead is acquiring PepStar's inflammation drug program for $1.28 billion, a development trending in Bend, OR and reported by centraloregondaily.com.
Bend, OR, October 23, 2026 —
Gilead is acquiring PepStar’s inflammation drug program for $1.28 billion, according to a trend summary that cites centraloregondaily.com. The development is trending in Bend, Oregon. The available information does not provide further details about the program or the transaction.
The summary does not identify the drug or drugs included in the program, describe the conditions they are intended to treat, or say what stage of development they have reached. It also does not specify when the acquisition was announced, when it is expected to close, or whether any approvals or other conditions apply.
The $1.28 billion figure is the only financial detail provided. The summary does not explain how that amount is structured, whether it includes payments tied to future events, or whether other financial terms were disclosed. No statements from Gilead or PepStar are included, and no rationale for the acquisition is given.
Although the development is described as trending in Bend, Oregon, the available information does not explain the connection to the city or identify any local effects. It also does not specify where either company is based or where the program’s research and development work takes place.
The report’s attribution is centraloregondaily.com, but the supplied summary does not include a direct link or additional reporting details. As a result, the timing, transaction terms, development plans and any subsequent steps remain unspecified in the information available here.
Story summarized from the original created by By Sahil Pandey on www.centraloregondaily.com, see more information here.
Media gallery
